Unknown PHASE2/PHASE3 INTERVENTIONAL NCT00197418

Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection

Dual Therapy With High-Dose of Rabeprazole and Amoxicilline Versus Triple Therapy With Rabeprazole, Amoxicilline and Metronidazole as the Second Line Therapy for the Cure of H. Pylori Infection

Sponsor: Hamamatsu University

Conditions Duodenal Ulcer Gastric Ulcer Gastritis Helicobacter Infections

Interventions rabeprazole, amoxicillin, clarithromycin, metronidazole

Updated 5 times since 2017 Last updated: Mar 20, 2006 Started: Aug 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Duodenal Ulcer and Gastric Ulcer and is currently ongoing. Hamamatsu University leads this study, which shows 5 recorded versions since 2003 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2_PHASE3

First recorded

Aug 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hamamatsu University

Data source: Hamamatsu University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hamamatsu, Japan